The Maharashtra Food and Drugs Administration (FDA) has detected 20 not-of-standard drugs during the month of April in the random sample testing. In April manufacturers from the tax-free state of Himachal Pradesh with 10 and Maharashtra with 5 not-of-standard drugs accounts for the major share.
Well-known drug manufacturers like ASA Biotech for Miscef-100, Athens Labs for RT-Zyme syrup, Ion Healthcare for Rabeprazole sodium tablets, Emcure Pharmaceuticals for Orofer XT suspension, Ciron Drugs & Pharmaceuticals for Co-Trimoxazole paediatric mixture IP/Co-Trimoxazol and Rhydburg Pharmaceuticals for Becoplex Forte also figure in the list.
Other highlights of Maha FDA's not-of-standard drugs list include - samples for not complying with IP requirements Atul Pharmaceuticals (Bethasone tablets), Affine Formulation (Prima 7.5 tablets/primaquine phosphate tablets), Ion Healthcare (Rabeprazole sodium tablets), Magbro Healthcare (Rabeprazole sodium tablets), Mission Laboratories (Healsera tablets), Prashi Pharma (Davithro 500/ Erythromycin stearate tablets).
Out of 20 such drug samples found in April, 10 were from Himachal Pradesh, five from Maharashtra, two from Gujarat and one each from Jammu and Kashmir, Uttaranchal and West Bengal.
During April other companies in the FDA list include: Atul Pharmaceuticals and S R Pharmaceuticals from Gujarat; Affine Formulation, ASA Biotech, Athens Labs, Elfin Drugs, Health Biotech, Ion Healthcare, Magbro Healthcare, Mission Laboratories, Orison Pharma International, Skyline Pharma from Himachal Pradesh, Emcure Pharmaceuticals from Jammu and Kashmir; Prashi Pharma, Snow Chem Industries, Zim Laboratories, Ciron Drugs and Pharmaceuticals from Maharashtra, Rhydburg Pharmaceuticals from Uttaranchal and C I Laboratories from West Bengal.
The state FDA routinely picks up random samples of drugs from chemists and druggists and sends for testing. The Department will soon issue show cause notices to these companies
